While the overwhelming majority of ALK-positive NSCLCs harbor an EML4–ALK fusion (83.5%), this chimeric transcript is encountered in only ~31% of ALK-rearranged non-NSCLC tumors, which instead display marked heterogeneity in 5′ fusion partners (16). This evidence concerns the gene EML4 and non-small cell lung carcinoma.